Clofibrate - CAS 637-07-0
Catalog number:
637-07-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C12H15ClO3
Molecular Weight:
242.7
COA:
Inquire
Targets:
PPAR
Description:
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Atromid-S
MSDS:
Inquire
1.Widely used pharmaceuticals present in the environment revealed as in vitro antagonists for human estrogen and androgen receptors.
Ezechiáš M1, Janochová J2, Filipová A2, Křesinová Z1, Cajthaml T3. Chemosphere. 2016 Jun;152:284-91. doi: 10.1016/j.chemosphere.2016.02.067. Epub 2016 Mar 12.
A considerable amount of scientific evidence indicates that a number of pharmaceuticals that could be detected in the environment can contribute towards the development of problems associated with human reproductive systems, as well as those of wildlife. We investigated the estrogenic and androgenic effects of select pharmaceuticals with high production volume and environmental relevance. We examined the receptor-binding activities of these pharmaceuticals in the T47D human cell line using altered secretion of cytokine CXCL12. Functional yeast-luciferase reporter gene assays were also employed to confirm the mechanism of receptor binding by estrogen and androgen. Non-steroidal anti-inflammatory drugs, namely ibuprofen, diclofenac and antiarrhythmic agent amiodarone showed strong anti-estrogenic effects in the T47D cell line. In the yeast-luciferase assay, these anti-inflammatory drugs also demonstrated anti-estrogenic potency and inhibited the E2 response in a concentration-dependent manner.
2.Involvement of Inflammatory Cytokines in Antiarrhythmic Effects of Clofibrate in Ouabain-Induced Arrhythmia in Isolated Rat Atria.
Moradi S1, Nikoui V2, Imran Khan M3, Amiri S4, Jazaeri F1, Bakhtiarian A4. Adv Pharmacol Sci. 2016;2016:9128018. doi: 10.1155/2016/9128018. Epub 2016 Feb 10.
Considering the cardioprotective and anti-inflammatory properties of clofibrate, the aim of the present experiment was to investigate the involvement of local and systemic inflammatory cytokines in possible antiarrhythmic effects of clofibrate in ouabain-induced arrhythmia in rats. Rats were orally treated with clofibrate (300 mg/kg), and ouabain (0.56 mg/kg) was administered to animals intraperitoneally. After induction of anesthesia, the atria were isolated and the onset of arrhythmia and asystole was recorded. The levels of inflammatory cytokines in atria were also measured. Clofibrate significantly postponed the onset of arrhythmia and asystole when compared to control group (P ≤ 0.05 and P ≤ 0.01, resp.). While ouabain significantly increased the atrial beating rate in control group (P ≤ 0.05), same treatment did not show similar effect in clofibrate-treated group (P > 0.05). Injection of ouabain significantly increased the atrial and systemic levels of all studied inflammatory cytokines (P ≤ 0.
3.Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats.
Muroya Y1, Ito O2. Clin Exp Nephrol. 2016 Mar 7. [Epub ahead of print]
BACKGROUND: Proteinuria plays an essential role in the progression of tubulointerstitial damage, which causes end-stage renal disease. An increased load of fatty acids bound to albumin reabsorbed into proximal tubular epithelial cells (PTECs) contributes to tubulointerstitial damage. Fibrates, agonists of peroxisome proliferator-activated receptor α (PPARα), have renoprotective effects against proteinuria whereas the effects of these compounds on fatty acid metabolism in the kidney are still unknown. Therefore, the present study examined whether the renoprotective effects of clofibrate were associated with improvement of fatty acid metabolism in puromycin aminonucleoside (PAN)-induced nephrotic rats.
4.Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction.
Ibarra-Lara ML1, Sánchez-Aguilar M1, Soria E2, Torres-Narváez JC1, Del Valle-Mondragón L1, Cervantes-Pérez LG1, Pérez-Severiano F3, Ramírez-Ortega MD1, Pastelín-Hernández G1, Oidor-Chan VH1,4, Sánchez-Mendoza A1. Can J Physiol Pharmacol. 2016 Jan 17:1-9. [Epub ahead of print]
Myocardial infarction (MI) has been associated with an inflammatory response and a rise in TNF-α, interleukin (IL)-1β, and IL-6. Peroxisome proliferator-activated receptors (PPARs) promote a decreased expression of inflammatory molecules. We aimed to study whether PPAR stimulation by clofibrate decreases inflammation and reduces infarct size in rats with MI. Male Wistar rats were randomized into 3 groups: control, MI + vehicle, and MI + clofibrate (100 mg/kg). Treatment was administered for 3 consecutive days, previous to 2 h of MI. MI induced an increase in protein expression, mRNA content, and enzymatic activity of inducible nitric oxide synthase (iNOS). Additionally, MI incited an increased expression of matrix metalloproteinase (MMP)-2 and MMP-9, intercellular adhesion molecule (ICAM)-1, and IL-6. MI also elevated the nuclear content of nuclear factor-κB (NF-κB) and decreased IκB, both in myocyte nuclei and cytosol. Clofibrate treatment prevented MI-induced changes in iNOS, MMP-2 and MMP-9, ICAM-1, IL-6, NF-κB, and IκB.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products


Saroglitazar
(CAS: 495399-09-2)

Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment...

CAS 188591-46-0 GSK-3787

GSK-3787
(CAS: 188591-46-0)

GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties.

CAS 863405-60-1 JW74

JW74
(CAS: 863405-60-1)

JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...

CAS 213411-84-8 BM152054

BM152054
(CAS: 213411-84-8)

BM152054, a thiazolidinedione, revealed to be potent PPARg-activators in transient transfection assays in vitro.

CAS 41859-67-0 Bezafibrate

Bezafibrate
(CAS: 41859-67-0)

Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...

GW-9820
(CAS: 195131-60-3)

GW-9820 is a PPAR-gamma agonist with potential antidiabetic effect.

CAS 313516-66-4 T0070907

T0070907
(CAS: 313516-66-4)

T0070907 was identified as a potent and selective PPARgamma antagonist. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte diffe...

CAS 108409-83-2 FH535

FH535
(CAS: 108409-83-2)

FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.

CAS 196808-24-9 GW1929

GW1929
(CAS: 196808-24-9)

A potent, tyrosine-based peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC50 = 13 nM for murine receptor and 6.2 nM for human receptor in cell-ba...

CAS 810677-36-2 PPARα-MO-1

PPARα-MO-1
(CAS: 810677-36-2)

A potent PPARα modulator

CDDO Imidazolide
(CAS: 443104-02-7)

CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...

CAS 50892-23-4 Pirinixic Acid

Pirinixic Acid
(CAS: 50892-23-4)

WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

CAS 317318-84-6 GW0742

GW0742
(CAS: 317318-84-6)

GW0742 is a potent and highly selective PPARβ/δ agonist, with IC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.

CAS 1014691-61-2 GSK0660

GSK0660
(CAS: 1014691-61-2)

GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...

CAS 637-07-0 Clofibrate

Clofibrate
(CAS: 637-07-0)

Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

CAS 52214-84-3 Ciprofibrate

Ciprofibrate
(CAS: 52214-84-3)

Ciprofibrate is a peroxisome proliferator-activated receptor agonist.

CAS 1453-93-6 PROTOPANAXATRIOL

PROTOPANAXATRIOL
(CAS: 1453-93-6)

Protopanaxatriol is a dammarane-type tetracyclic triterpene sapogenins found in ginseng (Panax ginseng) and in notoginseng (Panax pseudoginseng). It may have a ...

CAS 331741-94-7 Muraglitazar

Muraglitazar
(CAS: 331741-94-7)

Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).

CAS 213252-19-8 KRP297

KRP297
(CAS: 213252-19-8)

KRP297, also called as L4 10198 or MK 767, is a Peroxisome proliferator-activated receptor (PPAR) alpha and gamma (PPARα and PPARγ) agonist. With potential to t...

CAS 622402-22-6 GW-590735

GW-590735
(CAS: 622402-22-6)

GW-590735 is a potent and selective agonist of PPARα. Its EC50 value is 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivit...

Chemical Structure

CAS 637-07-0 Clofibrate

Quick Inquiry

Verification code

Featured Items